Drug therapy and prevalence of erectile dysfunction in the Massachusetts male aging study cohort

Carol A. Derby, M. M. Barbour, A. L. Hume, J. B. McKinlay

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Study Objective. To examine the association of commonly used drugs with erectile dysfunction (ED) at two time points. Design. Population-based, cross-sectional, survey analysis. Participants. Randomly selected cohort of men in the Massachusetts Male Aging Study (MMAS) that included 1476 men for the baseline (1987-1989) and 922 for the follow-up (1995-1997) analyses. Intervention. Crude associations between specific drug categories were examined with X2 statistics. Logistic regression analysis was used to separate the effect of drugs from the influence of heart disease, hypertension, untreated diabetes, or depressive symptoms. Measurements and Main Results. In the MMAS, medical history, current drug use, and erectile function status were ascertained with in-home interviews. In unadjusted analyses, thiazide and nonthiazide diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, benzodiazepines, digitalis, nitrates, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, and histamine2 receptor antagonists were associated with prevalent ED. Adjustment for comorbidities and health behaviors attenuated these associations, with only nonthiazide diuretics and benzodiazepines remaining statistically significant. Conclusion. Several common drugs may increase prevalence of ED; however, additional data from larger populations are needed to determine whether these associations are independent of underlying health conditions and to explore the effects of dosage and duration of use.

Original languageEnglish (US)
Pages (from-to)676-683
Number of pages8
JournalPharmacotherapy
Volume21
Issue number6
StatePublished - 2001
Externally publishedYes

Fingerprint

Erectile Dysfunction
Cohort Studies
Drug Therapy
Pharmaceutical Preparations
Benzodiazepines
Cross-Sectional Studies
Sodium Chloride Symporter Inhibitors
Digitalis
Health Behavior
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Nitrates
Population
Comorbidity
Heart Diseases
Oxidoreductases
Logistic Models
Regression Analysis
Interviews

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Drug therapy and prevalence of erectile dysfunction in the Massachusetts male aging study cohort. / Derby, Carol A.; Barbour, M. M.; Hume, A. L.; McKinlay, J. B.

In: Pharmacotherapy, Vol. 21, No. 6, 2001, p. 676-683.

Research output: Contribution to journalArticle

Derby, Carol A. ; Barbour, M. M. ; Hume, A. L. ; McKinlay, J. B. / Drug therapy and prevalence of erectile dysfunction in the Massachusetts male aging study cohort. In: Pharmacotherapy. 2001 ; Vol. 21, No. 6. pp. 676-683.
@article{2388859f0d1a4d6f89d31bf819a0a0d9,
title = "Drug therapy and prevalence of erectile dysfunction in the Massachusetts male aging study cohort",
abstract = "Study Objective. To examine the association of commonly used drugs with erectile dysfunction (ED) at two time points. Design. Population-based, cross-sectional, survey analysis. Participants. Randomly selected cohort of men in the Massachusetts Male Aging Study (MMAS) that included 1476 men for the baseline (1987-1989) and 922 for the follow-up (1995-1997) analyses. Intervention. Crude associations between specific drug categories were examined with X2 statistics. Logistic regression analysis was used to separate the effect of drugs from the influence of heart disease, hypertension, untreated diabetes, or depressive symptoms. Measurements and Main Results. In the MMAS, medical history, current drug use, and erectile function status were ascertained with in-home interviews. In unadjusted analyses, thiazide and nonthiazide diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, benzodiazepines, digitalis, nitrates, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, and histamine2 receptor antagonists were associated with prevalent ED. Adjustment for comorbidities and health behaviors attenuated these associations, with only nonthiazide diuretics and benzodiazepines remaining statistically significant. Conclusion. Several common drugs may increase prevalence of ED; however, additional data from larger populations are needed to determine whether these associations are independent of underlying health conditions and to explore the effects of dosage and duration of use.",
author = "Derby, {Carol A.} and Barbour, {M. M.} and Hume, {A. L.} and McKinlay, {J. B.}",
year = "2001",
language = "English (US)",
volume = "21",
pages = "676--683",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Drug therapy and prevalence of erectile dysfunction in the Massachusetts male aging study cohort

AU - Derby, Carol A.

AU - Barbour, M. M.

AU - Hume, A. L.

AU - McKinlay, J. B.

PY - 2001

Y1 - 2001

N2 - Study Objective. To examine the association of commonly used drugs with erectile dysfunction (ED) at two time points. Design. Population-based, cross-sectional, survey analysis. Participants. Randomly selected cohort of men in the Massachusetts Male Aging Study (MMAS) that included 1476 men for the baseline (1987-1989) and 922 for the follow-up (1995-1997) analyses. Intervention. Crude associations between specific drug categories were examined with X2 statistics. Logistic regression analysis was used to separate the effect of drugs from the influence of heart disease, hypertension, untreated diabetes, or depressive symptoms. Measurements and Main Results. In the MMAS, medical history, current drug use, and erectile function status were ascertained with in-home interviews. In unadjusted analyses, thiazide and nonthiazide diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, benzodiazepines, digitalis, nitrates, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, and histamine2 receptor antagonists were associated with prevalent ED. Adjustment for comorbidities and health behaviors attenuated these associations, with only nonthiazide diuretics and benzodiazepines remaining statistically significant. Conclusion. Several common drugs may increase prevalence of ED; however, additional data from larger populations are needed to determine whether these associations are independent of underlying health conditions and to explore the effects of dosage and duration of use.

AB - Study Objective. To examine the association of commonly used drugs with erectile dysfunction (ED) at two time points. Design. Population-based, cross-sectional, survey analysis. Participants. Randomly selected cohort of men in the Massachusetts Male Aging Study (MMAS) that included 1476 men for the baseline (1987-1989) and 922 for the follow-up (1995-1997) analyses. Intervention. Crude associations between specific drug categories were examined with X2 statistics. Logistic regression analysis was used to separate the effect of drugs from the influence of heart disease, hypertension, untreated diabetes, or depressive symptoms. Measurements and Main Results. In the MMAS, medical history, current drug use, and erectile function status were ascertained with in-home interviews. In unadjusted analyses, thiazide and nonthiazide diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, benzodiazepines, digitalis, nitrates, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, and histamine2 receptor antagonists were associated with prevalent ED. Adjustment for comorbidities and health behaviors attenuated these associations, with only nonthiazide diuretics and benzodiazepines remaining statistically significant. Conclusion. Several common drugs may increase prevalence of ED; however, additional data from larger populations are needed to determine whether these associations are independent of underlying health conditions and to explore the effects of dosage and duration of use.

UR - http://www.scopus.com/inward/record.url?scp=0034982344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034982344&partnerID=8YFLogxK

M3 - Article

C2 - 11401181

AN - SCOPUS:0034982344

VL - 21

SP - 676

EP - 683

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6

ER -